Chronic Myelomonocytic Leukemia Clinical Trial
Official title:
Clofarabine Followed by Lenalidomide for Treatment of High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
Background:
- Several types of blood cancer are associated with poor outcomes including high-risk
myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute
myelogenous leukemia (AML). Many people with MDS, CMML, and AML are not candidates for
standard treatments. New types of treatment are needed for these cancers.
- Clofarabine and lenalidomide are anticancer drugs. The first damages cancer cells in the
body. The second can alter blood supply to abnormal cells or affect how the immune
system attacks these cells. These drugs have been previously tested as treatments for
MDS and leukemia. However, they have not been tried as a combination for MDS, CMML, and
AML. Researchers want to see if these drugs are safe and effective for these types of
cancer.
Objectives:
- To test the safety and effectiveness of clofarabine and lenalidomide for people with
high-risk MDS, CMML, and AML.
Eligibility:
- Individuals at least 18 years of age who have high-risk MDS, CMML, and AML.
- Participants must not be candidates for standard treatments.
Design:
- Participants will be screened with a physical exam and medical history. Blood and bone
marrow samples will be collected.
- Participants will have 5 days of treatment with clofarabine. It will be given through a
vein during an inpatient hospital stay. If there are no serious side effects after the
infusion, participants will continue treatment as outpatients.
- After 28 days, participants will have a bone marrow biopsy to check their response to
treatment.
- After the biopsy, participants will start lenalidomide treatment. Half of the
participants will take the drug for 28 days (one treatment cycle). The other half will
take it for 56 days (two cycles). More blood tests and biopsies will be used to monitor
treatment.
- If there are no serious side effects and the disease does not become worse, participants
may keep taking lenalidomide at lower doses for up to 12 more cycles.
High risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute
myelogenous leukemia (AML) are hetereogeneous myeloid malignancies that are associated with a
poor prognosis. Due to advanced age and medical comorbidities, the majority of MDS, CMML, and
AML patients are not candidates for potentially curative standard treatments such as
allogeneic stem cell transplantation (SCT) or intensive chemotherapy (ICT). New therapeutic
approaches that improve response rates, have lesser toxicity, and extend survival are clearly
needed for high risk MDS and AML patients.
Clofarabine is a myelosuppressive, second generation purine nucleoside analogue which has
shown meaningful efficacy at variable dosing levels for high risk MDS and AML patients with a
favorable toxicity profile compared to intensive chemotherapy. Lenalidomide is an oral
structural analogue of thalidomide with a complex mechanism of action including
immunomodulatory, anti-angiogenic, and direct cytotoxic effects which is a well-established
treatment for MDS and has shown agent single efficacy at higher doses for AML. Lenalidomide s
therapeutic benefit in AML has been the greatest in patients with low presenting total
leukocyte and circulating blast counts. We hypothesize that the initial cytoreductive effects
of clofarabine may augment the effectiveness of subsequent lenalidomide therapy and create a
favorable immunologic milieu for patients eligible for lenalidomide maintenance therapy. This
open-label, single institution phase I trial will evaluate a sequential combination of IV
clofarabine with oral lenalidomide for the treatment of high risk MDS, CMML, and AML.
Subjects will receive a single course of IV clofarabine (5 milligrams per metered square per
day times 5) for cytoreduction. This will be followed by oral lenalidomide consolidation with
dose escalation from 25 mg daily for 21/28 days for 1 cycle in the first cohort up to 50 mg
daily for 28/28 days for 2 cycles in the fourth cohort. In the absence of dose limiting
toxicity or disease progression, Subjects will receive lenalidomide maintenance, starting at
a dose of 10 mg daily in 28 day cycles, with dose adjustments, for up to 12 cycles.
The overall objective is to determine the safety of sequential therapy with clofarabine and
lenalidomide in subjects with high risk MDS, CMML, and AML. The primary study endpoint will
be the toxicity profile of this novel treatment combination in each cohort. Secondary
endpoints will include characterization of response and duration, overall survival, and the
feasibility of maintenance lenalidomide therapy for responding subjects.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Active, not recruiting |
NCT03289910 -
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
|
Phase 2 | |
Recruiting |
NCT06159491 -
Pacritinib in CMML
|
Phase 1/Phase 2 | |
Completed |
NCT01427881 -
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
|
Phase 2 | |
Recruiting |
NCT01133886 -
Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure
|
Phase 2 | |
Completed |
NCT01233921 -
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
|
N/A | |
Completed |
NCT01169012 -
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias
|
Phase 1 | |
Completed |
NCT01093586 -
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
|
Phase 2 | |
Terminated |
NCT00509249 -
Aflibercept in Treating Patients With Myelodysplastic Syndromes
|
Phase 2 | |
Terminated |
NCT00387426 -
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
|
Phase 2 | |
Completed |
NCT00171912 -
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
|
Phase 2 | |
Completed |
NCT00096122 -
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
Completed |
NCT00078858 -
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
|
Phase 1/Phase 2 | |
Completed |
NCT00052520 -
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT03683433 -
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
|
Phase 2 | |
Recruiting |
NCT04980404 -
Inqovi Maintenance Therapy in Myeloid Neoplasms
|
Phase 1 | |
Active, not recruiting |
NCT03588078 -
Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine
|
Phase 1/Phase 2 | |
Withdrawn |
NCT06085638 -
Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT03999723 -
Combining Active and Passive DNA Hypomethylation
|
Phase 2 | |
Terminated |
NCT00852709 -
Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias
|
Phase 1 |